Document is current

Article History

Received: 8 October 2020

Accepted: 24 March 2021

First Online: 16 April 2021

Competing interests

: L. M. S. has acted in a consultancy or advisory role for AstraZeneca, Loxo Oncology at Lilly, Novartis, Pfizer, and Roche Genentech and has received research funding from AstraZeneca, Puma Biotechnology, and Roche Genentech, travel or accommodation expenses from Pfizer, Puma Biotechnology, and Roche Genentech, honoraria from AstraZeneca, Pfizer, and Roche Genentech, employment from Loxo Oncology at Lilly, and stock and other ownership interests from Lilly. G. B. has acted in a consultancy or advisory role for Roche. F. M.-B. has received commercial research grants from Abbvie, Aileron, AstraZeneca, Bayer, Calithera, Curis, CytoMx, Daiichi Sankyo, eFFECTOR, GlaxoSmithKline, Guardant Health, Jounce, Millennium, Novartis, PUMA Biotechnology, Seattle Genetics, Takeda, and Zymeworks, grants and travel-related fees from Debiopharm Group, Genentech, Pfizer, and Taiho, has acted in a consultancy role for Aduro, Dialectica, Jackson Laboratory, Kolon Life Science, OrigiMed, Parexel International, Pieris, Samsung Bioepis, Sumitomo Dainippon, Xencor, and Zymeworks, and in an advisory role for Darwin Health, GRAIL, Inflection Biosciences, Mersana, Seattle Genetics, and Spectrum. P. K. has performed contracted research for AstraZeneca, Eli Lilly, Genentech, Pfizer, Radius Health, and Sanofi. I. S. has received research funding from PUMA Biotechnology and travel expenses from BMS, Novartis, and Pfizer. K. J. has reported consultant and advisory board activities for Novartis, Spectrum Pharmaceuticals, ADC Therapeutics, Pfizer, Bristol-Myers Squibb, Jounce Therapeutics, and Taiho Oncology and research funding from Novartis, Clovis Oncology, Genentech, AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, and Pfizer. A. V. has received research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi and non-financial support from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. P. R. has performed consultation and attended advisory boards for Novartis and received institutional research funding from Grail, Inc and Illumina. U. B. has received research grants from AstraZeneca, Chugai, and Onyx Pharmaceuticals and consultancy fees from Astex and Novartis. D. M. H. reports stock ownership in Fount Therapeutics, has acted in a consultancy or advisory role for AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Genentech, and Pfizer, and has received research funding from AstraZeneca, Bayer, Loxo Oncology, and Puma Biotechnology and travel or accommodation expenses from Chugai Pharma and Genentech. S. C. has received a research grant from Daiichi Sankyo and consultancy fees from BMS, Context Therapeutics, Eli Lilly, Novartis, Revolution Medicines, and Sermonix Pharmaceutical. H. A., T. H. C., E. C. d. B., C. S.-S., A. F., J. H., J. P. O. L., R. Maudsley, R. McEwen, M. M., M. N., G. S., and J. B. are employees of AstraZeneca. A. L., A. W., and A. M. S. declare no conflict of interest.